Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke

Anna Kozak, Adviye Ergul, Azza B. El-Remessy, Maribeth H. Johnson, Livia S. Machado, Hazem F. Elewa, Mohammed Abdelsaid, Daniel C. Wiley, Susan C. Fagan

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background and Purpose-: We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown. We now examine effects of candesartan on proangiogenic factors and 7-day outcomes using the same treatment paradigm. Methods-: Male Wistar rats underwent 3 hours of middle cerebral artery occlusion followed by reperfusion. A single dose of 1 mg/kg candesartan intravenously was given at reperfusion. Animals received neurobehavioral testing before middle cerebral artery occlusion, at 24 hours after middle cerebral artery occlusion, and at 7 days. Blood pressure was measured by telemetry. Animals euthanized at 24 hours had brain tissue and cerebrospinal fluid collected for matrix metalloproteinase activity, vascular endothelial growth factor expression, and tube formation assay. Neurobehavioral testing included elevated body swing test, Bederson, beam walk, and paw grasp. Cerebrovascular density was quantified using immunohistochemistry at 24 hours and 7 days. Results-: Matrix metalloproteinase-2 activity and vascular endothelial growth factor expression were higher (P=0.035, P=0.042, respectively) and cerebrospinal fluid was significantly more proangiogenic (5× tube formation; P=0.002) in the candesartan group at 24 hours. Although no difference was seen in infarct size at 7 days, treatment improved Bederson scores (2.1 versus 2.9, P=0.0083), elevated body swing test (22.9 versus 39.4, P=0.021), and paw grasp (1.29 versus 2.88, P=0.0001) at 7 days. Candesartan treatment resulted in increased vascular density in the striatum at 7 days (P=0.037). Conclusion-: Candesartan after reperfusion augments ischemia-induced angiogenic state and provides long-term benefits. The beneficial effects may involve vascular protection and enhancement of early angiogenic remodeling.

Original languageEnglish (US)
Pages (from-to)1870-1876
Number of pages7
JournalStroke
Volume40
Issue number5
DOIs
StatePublished - May 1 2009

Fingerprint

Ischemia
Stroke
Middle Cerebral Artery Infarction
Reperfusion
Blood Vessels
Hand Strength
Vascular Endothelial Growth Factor A
Cerebrospinal Fluid
Telemetry
Matrix Metalloproteinase 2
Therapeutics
Matrix Metalloproteinases
candesartan
Wistar Rats
Theoretical Models
Immunohistochemistry
Blood Pressure
Brain

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Kozak, A., Ergul, A., El-Remessy, A. B., Johnson, M. H., Machado, L. S., Elewa, H. F., ... Fagan, S. C. (2009). Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke, 40(5), 1870-1876. https://doi.org/10.1161/STROKEAHA.108.537225

Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. / Kozak, Anna; Ergul, Adviye; El-Remessy, Azza B.; Johnson, Maribeth H.; Machado, Livia S.; Elewa, Hazem F.; Abdelsaid, Mohammed; Wiley, Daniel C.; Fagan, Susan C.

In: Stroke, Vol. 40, No. 5, 01.05.2009, p. 1870-1876.

Research output: Contribution to journalArticle

Kozak, A, Ergul, A, El-Remessy, AB, Johnson, MH, Machado, LS, Elewa, HF, Abdelsaid, M, Wiley, DC & Fagan, SC 2009, 'Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke', Stroke, vol. 40, no. 5, pp. 1870-1876. https://doi.org/10.1161/STROKEAHA.108.537225
Kozak, Anna ; Ergul, Adviye ; El-Remessy, Azza B. ; Johnson, Maribeth H. ; Machado, Livia S. ; Elewa, Hazem F. ; Abdelsaid, Mohammed ; Wiley, Daniel C. ; Fagan, Susan C. / Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. In: Stroke. 2009 ; Vol. 40, No. 5. pp. 1870-1876.
@article{01624e3ea01246a2a703eaff57a79f8f,
title = "Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke",
abstract = "Background and Purpose-: We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown. We now examine effects of candesartan on proangiogenic factors and 7-day outcomes using the same treatment paradigm. Methods-: Male Wistar rats underwent 3 hours of middle cerebral artery occlusion followed by reperfusion. A single dose of 1 mg/kg candesartan intravenously was given at reperfusion. Animals received neurobehavioral testing before middle cerebral artery occlusion, at 24 hours after middle cerebral artery occlusion, and at 7 days. Blood pressure was measured by telemetry. Animals euthanized at 24 hours had brain tissue and cerebrospinal fluid collected for matrix metalloproteinase activity, vascular endothelial growth factor expression, and tube formation assay. Neurobehavioral testing included elevated body swing test, Bederson, beam walk, and paw grasp. Cerebrovascular density was quantified using immunohistochemistry at 24 hours and 7 days. Results-: Matrix metalloproteinase-2 activity and vascular endothelial growth factor expression were higher (P=0.035, P=0.042, respectively) and cerebrospinal fluid was significantly more proangiogenic (5× tube formation; P=0.002) in the candesartan group at 24 hours. Although no difference was seen in infarct size at 7 days, treatment improved Bederson scores (2.1 versus 2.9, P=0.0083), elevated body swing test (22.9 versus 39.4, P=0.021), and paw grasp (1.29 versus 2.88, P=0.0001) at 7 days. Candesartan treatment resulted in increased vascular density in the striatum at 7 days (P=0.037). Conclusion-: Candesartan after reperfusion augments ischemia-induced angiogenic state and provides long-term benefits. The beneficial effects may involve vascular protection and enhancement of early angiogenic remodeling.",
author = "Anna Kozak and Adviye Ergul and El-Remessy, {Azza B.} and Johnson, {Maribeth H.} and Machado, {Livia S.} and Elewa, {Hazem F.} and Mohammed Abdelsaid and Wiley, {Daniel C.} and Fagan, {Susan C.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1161/STROKEAHA.108.537225",
language = "English (US)",
volume = "40",
pages = "1870--1876",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke

AU - Kozak, Anna

AU - Ergul, Adviye

AU - El-Remessy, Azza B.

AU - Johnson, Maribeth H.

AU - Machado, Livia S.

AU - Elewa, Hazem F.

AU - Abdelsaid, Mohammed

AU - Wiley, Daniel C.

AU - Fagan, Susan C.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Background and Purpose-: We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown. We now examine effects of candesartan on proangiogenic factors and 7-day outcomes using the same treatment paradigm. Methods-: Male Wistar rats underwent 3 hours of middle cerebral artery occlusion followed by reperfusion. A single dose of 1 mg/kg candesartan intravenously was given at reperfusion. Animals received neurobehavioral testing before middle cerebral artery occlusion, at 24 hours after middle cerebral artery occlusion, and at 7 days. Blood pressure was measured by telemetry. Animals euthanized at 24 hours had brain tissue and cerebrospinal fluid collected for matrix metalloproteinase activity, vascular endothelial growth factor expression, and tube formation assay. Neurobehavioral testing included elevated body swing test, Bederson, beam walk, and paw grasp. Cerebrovascular density was quantified using immunohistochemistry at 24 hours and 7 days. Results-: Matrix metalloproteinase-2 activity and vascular endothelial growth factor expression were higher (P=0.035, P=0.042, respectively) and cerebrospinal fluid was significantly more proangiogenic (5× tube formation; P=0.002) in the candesartan group at 24 hours. Although no difference was seen in infarct size at 7 days, treatment improved Bederson scores (2.1 versus 2.9, P=0.0083), elevated body swing test (22.9 versus 39.4, P=0.021), and paw grasp (1.29 versus 2.88, P=0.0001) at 7 days. Candesartan treatment resulted in increased vascular density in the striatum at 7 days (P=0.037). Conclusion-: Candesartan after reperfusion augments ischemia-induced angiogenic state and provides long-term benefits. The beneficial effects may involve vascular protection and enhancement of early angiogenic remodeling.

AB - Background and Purpose-: We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown. We now examine effects of candesartan on proangiogenic factors and 7-day outcomes using the same treatment paradigm. Methods-: Male Wistar rats underwent 3 hours of middle cerebral artery occlusion followed by reperfusion. A single dose of 1 mg/kg candesartan intravenously was given at reperfusion. Animals received neurobehavioral testing before middle cerebral artery occlusion, at 24 hours after middle cerebral artery occlusion, and at 7 days. Blood pressure was measured by telemetry. Animals euthanized at 24 hours had brain tissue and cerebrospinal fluid collected for matrix metalloproteinase activity, vascular endothelial growth factor expression, and tube formation assay. Neurobehavioral testing included elevated body swing test, Bederson, beam walk, and paw grasp. Cerebrovascular density was quantified using immunohistochemistry at 24 hours and 7 days. Results-: Matrix metalloproteinase-2 activity and vascular endothelial growth factor expression were higher (P=0.035, P=0.042, respectively) and cerebrospinal fluid was significantly more proangiogenic (5× tube formation; P=0.002) in the candesartan group at 24 hours. Although no difference was seen in infarct size at 7 days, treatment improved Bederson scores (2.1 versus 2.9, P=0.0083), elevated body swing test (22.9 versus 39.4, P=0.021), and paw grasp (1.29 versus 2.88, P=0.0001) at 7 days. Candesartan treatment resulted in increased vascular density in the striatum at 7 days (P=0.037). Conclusion-: Candesartan after reperfusion augments ischemia-induced angiogenic state and provides long-term benefits. The beneficial effects may involve vascular protection and enhancement of early angiogenic remodeling.

UR - http://www.scopus.com/inward/record.url?scp=65549163364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549163364&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.108.537225

DO - 10.1161/STROKEAHA.108.537225

M3 - Article

C2 - 19265050

AN - SCOPUS:65549163364

VL - 40

SP - 1870

EP - 1876

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 5

ER -